Egetis Therapeutics AB is a pharmaceutical company based in Stockholm that specializes in developing innovative therapies for rare diseases. The company is known for its lead product, Emcitate® (tiratricol), which is part of its active clinical pipeline. Egetis is engaged in ongoing research to advance its therapeutic offerings, demonstrating a commitment to addressing unmet medical needs in the rare disease space.
The company places a strong emphasis on transparency and communication with its stakeholders, regularly issuing press releases to provide updates on its progress and initiatives. Egetis also offers corporate presentations aimed at providing insights for investors. Additionally, the company engages in community storytelling, exemplified by initiatives like Joshua’s Story, which highlights the impact of its work on patients' lives. Egetis Therapeutics AB is dedicated to fostering awareness and collaboration through various events and by making access to reports and presentations readily available.